Abacus.AI – ChatLLM Teams
One AI Assistant To Rule Them All. Use One AI Assistant To Access All The SOTA LLMs
Related Articles
Broadening perspectives in interventional cardiology. The role of EAPCI in supporting interventional cardiologists
Erik Rafflenbeul, a, Mario Iannaccone, b Aleksandra Gasecka, c Nicola Ryan, d and Alaide Chieffo e, f a Department of Cardiology, Schoen Clinic Hamburg Eilbek,…
Hypothyroidism and the heart
My name is sanjay gupta and I am a cardiologist who believes in the concept of making high quality, jargon-free, holistic information about heart health…
Long Context vs. RAG for LLMs: An Evaluation and Revisits
Extending context windows (i.e., Long Context, LC) and using retrievers to selectively access relevant information (i.e., Retrieval-Augmented Generation, RAG) are the two main strategies to…
Cornellius Y. on LinkedIn: Evaluating LLM Models for Production Systems
LLM systems in production environments are more complex than traditional ML evaluation. It requires task-specific and semantic assessments due to the diverse…
How to remove Matrix Multiplications from LLMs
10x Efficiency, Good Performance, and comparable scaling
yasserrmd/SmallThinker-3B-Preview-gguf · Hugging Face
We’re on a journey to advance and democratize artificial intelligence through open source and open science.
Google Gemini is racing to win the AI crown in 2025
Can it catch up and beat ChatGPT, Meta, and Apple?
Hybrid Search Is the Future of GenAI Applications!
In this highly competitive AI era, automation and data is king. The ability to efficiently automate the process of search and retrieval of…
Intervención pionera en el Chuac: un corazón artificial logra la recuperación de una niña de un año y evita un trasplante
Nunca en España se había logrado una recuperación como la de la menor, que padecía una miocarditis fulminante por infección por parvovirus
CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy | NEJM
Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a progressive, often fatal disease. Nexiguran ziclumeran (nex-z) is an investigational therapy based on CRISPR-Cas9 (clustered regularly i…
